Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acr
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| (NASDAQ: LSTA) | Delayed: 1.01 -0.04 (3.81%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.05 | 52 Week High | $ | |||
| Open | $1.06 | 52 Week Low | $ | |||
| Day High | $1.06 | P/E | N/A | |||
| Day Low | $1.00 | EPS | $ | |||
| Volume | 27,669 | |||||
